Hyphens Pharma (SGX:1J5), through Hyphens Pharma International, launched Winlevi (clascoterone) cream 1% in Singapore and Malaysia, according to a Thursday filing with the Singapore Exchange.
Shares of the company were up nearly 2% in recent trading.
The launch comes after the company entered into an exclusive license and supply agreement with Cosmo Pharmaceuticals subsidiary Cassiopea.
The acne cream provides treatment for acne-related inflammation.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。